Ramsey, Haley E.
Stengel, Kristy
Pino, James C.
Johnston, Gretchen
Childress, Merrida
Gorska, Agnieszka E.
Arrate, Pia M.
Fuller, Londa
Villaume, Matthew
Fischer, Melissa A.
Ferrell, P. Brent Jr.
Roe, Caroline E.
Zou, Jing
Lubbock, Alexander L. R.
Stubbs, Matthew
Zinkel, Sandra
Irish, Jonathan M.
Lopez, Carlos F.
Hiebert, Scott
Savona, Michael R.
Funding for this research was provided by:
Incyte Research Institute and the Vanderbilt-Incyte Research Alliance Grant
Leukemia and Lymphoma Society
E.P. Evans Foundation Discovery Research
Adventure Allie Discovery Research Fund
Biff Ruttenburg Foundation
National Institutes of Health (NIH P30 CA068485-19)
National Institutes of Health (UL1 TR000445)
Article History
Accepted: 19 July 2021
First Online: 29 July 2021
Declarations
:
: This study was supported by the Incyte Research Institute and the Vanderbilt-Incyte Research Alliance Grant (B. Ferrell, S.Zinkel, J. Irish, C. Lopez, S. Hiebert, M.Savona). M. Savona is a Leukemia and Lymphoma Society Clinical Scholar, and is supported by the E.P. Evans Foundation Discovery Research Grant, the Adventure Allie Discovery Research Fund (M. Savona), the Biff Ruttenburg Foundation (M. Savona), the Beverly and George Rawlings Directorship and the NIH. The Vanderbilt-Ingram Cancer Center is supported by a NIH P30 CA068485-19. The REDCap database tool is supported by grant UL1 TR000445 from NCATS/NIH. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
: B. Ferrell received research funding for Astex, Forma, and Incyte. S.Zinkel, J. Irish, and C. Lopez received research funding from Incyte. M. Stubbs is an employee of Incyte Research Institute and owns equity in Incyte. S. Hiebert received research support from Incyte through the Vanderbilt-Incyte Research Alliance Grant. M. Savona receives research funding from ALX Oncology, Astex, Incyte, Takeda, and TG Therapeutics; has equity with Karyopharm; serves as an advisory or consultant to AbbVie, Astex, BMS, Celgene, Geron, Incyte, Karyopharm, Ryvu, Sierra Oncology, Taiho, Takeda, TG Therapeutics. Haley E. Ramsey, Kristy Stengel, James C. Pino, Gretchen Johnston, Merrida Childress, Agnieszka E. Gorska, Pia M. Arrate , Londa Fuller, Matthew Villaume, Melissa A. Fischer, Caroline E. Roe, Jing Zou<b>,</b> and Alexander L.R. Lubbock declare that they have no conflicts of interest that might be relevant to the contents of this article.
: Conception and design: HER, MS, SH, MRS. Development of methodology: HER, AEG, PMA, MAF, MS, SH, MRS. Acquisition of data (provided animals, acquired and managed patient samples, provided facilities, etc.): HER, AEG, PMA, LF, MV, MS. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): HER, JCP, MC, AEG, PMA, CFL, SH, MRS. Writing, review, and/or revision of the manuscript: All authors. Administrative, technical, or material support (i.e., reporting or organizing data, constructing database): HER, PMA, KS, JCP, GJ, MC, AEG, PMA, LF, MAF, MRS. Study supervision: MRS.
: All data generated or analyzed during this study are included in this published article (and its supplementary information files).
: Not applicable.
: All animal studies were conducted in accordance to guidelines approved by the IACUC at Vanderbilt University Medical Center.
: Not applicable.
: Not applicable.